| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Crescent Biopharma, Inc. (CBIO) has 13 insiders with recent SEC Form 4 filings, including 1 buy and 14 sells. CBIO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 2.75M | $48.61M | - | |
| CEO | 323.5K | $5.72M | - | |
| COO | 153.7K | $2.72M | - | |
| Other | 70.0K | $1.24M | - | |
| Other | 54.2K | $958.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 10, 2018 | Barrett M James | Director, 10% Owner | Sell | 9,539 | $17.81 | $169,889.59 | - | |
| May 10, 2018 | Barris Peter J | 10% Owner | Sell | 9,539 | $17.81 | $169,889.59 | - | |
| Dec 8, 2017 | Thackray Helen M.78 | SVP Clinical Development, CMO | Sell | 2,000 | $15.01 | $30,020.00 | -1.3% | |
| Sep 18, 2017 | Thackray Helen M.78 | SVP Clinical Development, CMO | Sell | 2,000 | $13.00 | $26,000.00 | -1.3% | |
| May 25, 2017 | Thackray Helen M.78 | SVP Clinical Development, CMO | Sell | 2,000 | $15.57 | $31,140.00 | -1.3% | |
| May 19, 2017 | Thackray Helen M.78 | SVP Clinical Development, CMO | Sell | 2,000 | $12.14 | $24,280.00 | -1.3% | |
| Dec 20, 2016 | Junius Daniel M | Director | Buy | 5,000 | $6.01 | $30,050.00 | New | |
| Oct 3, 2016 | Thackray Helen M.78 | VP Clinical Development, CMO | Sell | 4,000 | $7.00 | $28,001.00 | -1.3% | |
| Jul 20, 2016 | Thackray Helen M.78 | VP Clinical Development, CMO | Sell | 2,000 | $8.00 | $16,000.00 | -1.2% | |
| Jul 6, 2016 | Thackray Helen M.78 | VP Clinical Development, CMO | Sell | 22,000 | $7.00 | $153,953.84 | -4.1% |